Pharmicell, a leading stem cell therapy company, announced on November 27 that it has signed a contract with Asan Medical Center in Seoul to supply contract manufacturing organization (CMO) services for stem cells used in advanced regenerative medicine clinical research.
Through this agreement, Pharmicell will manufacture and supply cell therapy products for Asan Medical Center’s advanced regenerative medicine clinical research at its second GMP plant’s cell processing facility. The company expects this to demonstrate its production capabilities in the field of advanced regenerative medicine. The specific terms of the contract will not be disclosed, as agreed upon by both parties.
Recently, Pharmicell obtained licenses for the management of human cells and cell processing facilities, expanding its scope from existing bone marrow- and adipose-derived mesenchymal stem cells to include umbilical cord-derived mesenchymal stem cells. In addition, with over 20 years of accumulated experience in stem cell therapy production, state-of-the-art GMP manufacturing facilities, and an established quality management system, the company possesses CDMO capabilities that support the entire process from early-stage research and development to clinical trials and commercialization.
A Pharmicell representative stated, “Our total cell platform, which includes manufacturing licenses for advanced biopharmaceuticals, management of human cells, cell processing facility permits, and GMP compliance certification, is a unique competitive advantage for Pharmicell.” The representative added, “We will continue to expand our collaboration with advanced regenerative medicine institutions in the growing regenerative medicine market, leveraging our integrated infrastructure.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
